Harvard Management Company’s Sana Biotechnology SANA Stock Holding History

Harvard Management Company’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-216,376	Closed	-$837K	–	17
2023 Q3	$837K	Sell	216,376 -252,373	-54%	-$1.36M	0.09%	20
2023 Q2	$2.79M	Hold	468,749	–	–	0.27%	20
2023 Q1	$1.53M	Hold	468,749	–	–	0.16%	35
2022 Q4	$1.85M	Hold	468,749	–	–	0.23%	36
2022 Q3	$2.81M	Hold	468,749	–	–	0.35%	30
2022 Q2	$3.01M	Hold	468,749	–	–	0.35%	32
2022 Q1	$3.87M	Hold	468,749	–	–	0.39%	32
2021 Q4	$7.26M	Sell	468,749 -694,852	-60%	-$13.4M	0.68%	33
2021 Q3	$26.2M	Buy	1,163,601 +694,852	+148%	+$14.6M	1.54%	12
2021 Q2	$9.22M	Hold	468,749	–	–	0.53%	23
2021 Q1	$15.7M	Buy	+468,749	New	+$15.3M	0.88%	19

Other funds holding SANA

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Harvard Management Company's SANA Position: Q4 2023 in Review

Harvard Management Company sold out of Sana Biotechnology (SANA) in Q4 2023, closing a stake of 216,376 shares — an estimated $837K sold.

Harvard Management Company first reported a position in SANA in Q1 2021 and held it in 11 quarters. The position peaked at $26.2M in Q3 2021. 132 funds tracked by Wall St. Rank hold SANA as of Q4 2023.

Harvard Management Company reported no remaining Sana Biotechnology position as of Q4 2023 after selling out during the quarter.
Harvard Management Company sold 216,376 Sana Biotechnology shares in Q4 2023, an estimated $837K.
Harvard Management Company first reported a position in Sana Biotechnology in Q1 2021 and held it in 11 quarters.
Harvard Management Company's Sana Biotechnology position peaked at $26.2M in Q3 2021.
132 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2023.

Based on Harvard Management Company's 13F filing for Q4 2023, filed 9 Feb 2024.